<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref35">
 <mixed-citation publication-type="journal" id="cit35">
  <name>
   <surname>Richardson</surname>
   <given-names>P.</given-names>
  </name>; 
  <name>
   <surname>Griffin</surname>
   <given-names>I.</given-names>
  </name>; 
  <name>
   <surname>Tucker</surname>
   <given-names>C.</given-names>
  </name>; 
  <name>
   <surname>Smith</surname>
   <given-names>D.</given-names>
  </name>; 
  <name>
   <surname>Oechsle</surname>
   <given-names>O.</given-names>
  </name>; 
  <name>
   <surname>Phelan</surname>
   <given-names>A.</given-names>
  </name>; 
  <name>
   <surname>Stebbing</surname>
   <given-names>J.</given-names>
  </name>
  <article-title>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</article-title>. 
  <source>Lancet</source>
  <year>2020</year>, 
  <volume>395</volume> (
  <issue>10223</issue>), 
  <fpage>e30</fpage>â€“
  <lpage>e31</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30304-4</pub-id>.
  <pub-id pub-id-type="pmid">32032529</pub-id>
 </mixed-citation>
</ref>
